.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Citi
Colorcon
Dow
Argus Health
Express Scripts
Johnson and Johnson
Federal Trade Commission
Cantor Fitzgerald
Mallinckrodt

Generated: November 19, 2017

DrugPatentWatch Database Preview

Valeant Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT, and when can generic versions of VALEANT drugs launch?

VALEANT has one hundred and twenty-five approved drugs.

There are forty-seven US patents protecting VALEANT drugs.

There are eight hundred and two patent family members on VALEANT drugs in fifty-five countries and sixty-four supplementary protection certificates in twelve countries.

Summary for Valeant

International Patents:802
US Patents:47
Tradenames:102
Ingredients:80
NDAs:125
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North
IPRIVASK
desirudin recombinant
INJECTABLE;SUBCUTANEOUS021271-001Apr 4, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms North
APLENZIN
bupropion hydrobromide
TABLET, EXTENDED RELEASE;ORAL022108-002Apr 23, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Valeant Intl
RETIN-A-MICRO
tretinoin
GEL;TOPICAL020475-003Jan 28, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharm Intl
LIBRIUM
chlordiazepoxide hydrochloride
CAPSULE;ORAL012249-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm Intl
MEPROBAMATE
meprobamate
TABLET;ORAL015139-006Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms North
CARAC
fluorouracil
CREAM;TOPICAL020985-001Oct 27, 2000ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Bermuda
XERESE
acyclovir; hydrocortisone
CREAM;TOPICAL022436-001Jul 31, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms North
ISORDIL
isosorbide dinitrate
TABLET;ORAL012093-001Jul 29, 1988RXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharm Intl
SODIUM PENTOBARBITAL
pentobarbital sodium
CAPSULE;ORAL083264-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms North
DIASTAT
diazepam
GEL;RECTAL020648-003Jul 29, 1997DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Intl
UCERIS
budesonide
AEROSOL, FOAM;RECTAL205613-001Oct 7, 2014► Subscribe► Subscribe
Valeant Pharm Intl
PERMAX
pergolide mesylate
TABLET;ORAL019385-003Dec 30, 1988► Subscribe► Subscribe
Valeant Pharms Intl
COLAZAL
balsalazide disodium
CAPSULE;ORAL020610-001Jul 18, 2000► Subscribe► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-001Feb 6, 2003► Subscribe► Subscribe
Valeant Intl
CARDIZEM CD
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020062-004Dec 27, 1991► Subscribe► Subscribe
Valeant Pharm Intl
PERMAX
pergolide mesylate
TABLET;ORAL019385-002Dec 30, 1988► Subscribe► Subscribe
Valeant Intl
VASERETIC
enalapril maleate; hydrochlorothiazide
TABLET;ORAL019221-001Oct 31, 1986► Subscribe► Subscribe
Valeant Pharms
ULTRAM ER
tramadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL021692-003Sep 8, 2005► Subscribe► Subscribe
Valeant Intl
CARDIZEM
diltiazem hydrochloride
TABLET;ORAL018602-003Dec 8, 1986► Subscribe► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-006Feb 6, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VALEANT drugs

Drugname Dosage Strength Tradename Submissiondate
ribavirin
For Inhalation Solution6 gm/vial
VIRAZOLE
5/22/2014
balsalazide disodium
Tablets1.1 g
GIAZO
11/5/2013
budesonide
Extended-release Tablets9 mg
UCERIS
3/11/2013
mesalamine
Extended-release Capsules0.375 g
APRISO
4/3/2012
fluorouracil
Cream0.5%
CARAC
7/29/2011
bexarotene
Capsules75 mg
TARGRETIN
6/6/2011
tretinoin
Gel0.04%
RETIN-A MICRO
12/20/2010
tretinoin
Gel0.1%
RETIN-A MICRO
7/8/2010
bupropion hydrobromide
Extended-release Tablets522 mg
APLENZIN
12/24/2009
bupropion hydrobromide
Extended-release Tablets174 mg
APLENZIN
9/28/2009
bupropion hydrobromide
Extended-release Tablets348 mg
APLENZIN
9/24/2009
diazepam
Rectal Gel5 mg/mL, 2mL pre-filled syringe
DIASTAT ACUDIAL
12/23/2008
diazepam
Rectal Gel5 mg/mL, 4mL pre-filled syringe
DIASTAT ACUDIAL
12/8/2008
tramadol hydrochloride
Extended-release Tablets300 mg
ULTRAM ER
9/25/2007
tramadol hydrochloride
Extended-release Tablets200 mg
ULTRAM ER
3/28/2007
tramadol hydrochloride
Extended-release Tablets100 mg
ULTRAM ER
1/8/2007
diltiazem hydrochloride
Extended-release Tablets120 mg, 180 mg, 240 mg, 300 mg and 360 mg
CARDIZEM LA
8/30/2005
diltiazem hydrochloride
Extended-release Tablets420 mg
CARDIZEM LA
4/25/2005
bupropion hydrochloride
Extended-release Tablets150 mg and 300 mg
WELLBUTRIN XL
9/21/2004
diazepam
Rectal Gel2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL
DIASTAT
3/23/2004

Premature patent expirations for VALEANT

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Valeant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,780,676 Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors► Subscribe
7,939,654Platelet derived growth factor (PDGF) nucleic acid ligand complexes► Subscribe
6,855,496 Truncation SELEX method► Subscribe
7,629,151Method and apparatus for the automated generation of nucleic acid ligands► Subscribe
5,795,721 High affinity nucleic acid ligands of ICP4► Subscribe
5,753,494 Method and apparatus for treating contaminated soils with ozone► Subscribe
6,716,580 Method for the automated generation of nucleic acid ligands► Subscribe
5,639,868 High-affinity RNA ligands for basic fibroblast growth factor► Subscribe
7,368,236Methods of producing nucleic acid ligands► Subscribe
5,595,877 Methods of producing nucleic acid ligands► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Drugs

Country Document Number Estimated Expiration
Hong Kong1004368► Subscribe
European Patent Office2563117► Subscribe
MexicoPA02000819► Subscribe
Canada2380473► Subscribe
Brazil0013170► Subscribe
Australia4682196► Subscribe
Portugal1131057► Subscribe
European Patent Office1564290► Subscribe
South Korea20000052697► Subscribe
European Patent Office0840739► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041Netherlands► SubscribePRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
C/GB01/041United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
C0114Belgium► SubscribePRODUCT NAME: DESIRUDIN; REGISTRATION NO/DATE: EU/1/97/043/001 19970709
0234Netherlands► Subscribe300234, 20171017, EXPIRES: 20210130
C/GB01/005United Kingdom► SubscribePRODUCT NAME: VERTEPORFIN OPTIONALLY IN THE FORM OF A SALT THEREOF; REGISTERED: UK EU/1/00/140/001 20000727
00037Netherlands► SubscribePRODUCT NAME: VERTEPORFINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/00/140/001 20000727
172Luxembourg► SubscribePRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
C013/2001Ireland► SubscribeSPC013/2001: 20031205, EXPIRES: 20160328
00043Netherlands► SubscribePRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Army
Johnson and Johnson
McKesson
Dow
Healthtrust
Merck
Novartis
Julphar
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot